Imaging and biopsy during a planned HIV treatment pause
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 study uses special scans (PET/CT) and tissue sampling (biopsy) to learn what is happening in the body while people with HIV take a planned break from antiretroviral therapy (ART) for up to 90 days. It may help researchers find better ways to control HIV without ongoing treatment, though joining involves careful monitoring during the pause.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older.
- Have HIV-1 confirmed with CDC-recommended testing, and be in regular medical care outside NIH.
- Be on ART (HIV treatment) and have an undetectable viral load under 40 copies/mL for at least 3 years (small brief “blips” may be allowed).
- Have CD4 counts of at least 350 cells in each microliter of blood.
- Be willing to stop ART for up to 90 days and attend frequent study visits.
- Be willing to store samples for future research and do genetic testing; also use pregnancy prevention (condoms/dental dams) or stay abstinent until the virus becomes controlled again after restarting ART.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
This study looks at what happens when HIV treatment (ART) is intentionally paused in people who are already enrolled in a specific research study (RV254) and recently joined a protocol that included an earlier treatment pause. It may help researchers understand safety and how to manage treatment changes, but it has strict participation and consent requirements.
This study looks at whether some people with HIV can keep the virus controlled even if they temporarily stop HIV medicines (an “analytic treatment interruption”). If you qualify, it may help researchers learn what it would take for an HIV cure.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
This study tests whether giving a small protein called IL-15 can help your immune system keep HIV under control after pausing your daily HIV medications. You will stop your meds for a short time under careful monitoring, and the hope is that your body might learn to fight HIV without daily pills.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.